Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular function

American Heart Journal

Volumn 151, Issue 3, 2006, Pages 745-753

  Isbel, Nicole M ^a,b   Haluska, Brian ^b   Johnson, David W ^a,b   Beller, Elaine ^b   Hawley, Carmel ^a   Marwick, Thomas H ^b  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALUMINUM HYDROXIDE; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; CALCIUM CARBONATE; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; FOLIC ACID; HEMOGLOBIN; HOMOCYSTEINE; HYDROXOCOBALAMIN; IRON; PHOSPHATE; PYRIDOXINE; SEVELAMER;

ACUTE CORONARY SYNDROME; ADULT; AMPUTATION; ANEMIA; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; ATHEROMA; BLOOD PRESSURE; BLOOD VESSEL WALL; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSIS; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DYSLIPIDEMIA; ENDOTHELIUM; FEMALE; FOLLOW UP; HEART MUSCLE REVASCULARIZATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERPHOSPHATEMIA; HYPERTENSION; INTENSIVE CARE; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; NURSE; OUTCOME ASSESSMENT; PHOSPHATE BLOOD LEVEL; PHYSICIAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING; STATISTICAL SIGNIFICANCE; STROKE; SYSTOLIC BLOOD PRESSURE;

ADULT; BLOOD PRESSURE; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CHRONIC DISEASE; ENDOTHELIUM, VASCULAR; HUMANS; HYPERHOMOCYSTEINEMIA; KIDNEY DISEASES; MALE; MIDDLE AGED; PATIENT CARE MANAGEMENT; RISK FACTORS;

EID: 33344475783     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2005.06.017     Document Type: Article

References (35)

1. A.S. Go, G.M. Chertow, and D. Fan Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 2004 1296 1305
2. R.N. Foley, P.S. Parfrey, and M.J. Sarnak Epidemiology of cardiovascular disease in chronic renal disease J Am Soc Nephrol 9 1998 S16 S23
3. A.J. Collins Cardiovascular mortality in end-stage renal disease Am J Med Sci 325 2003 163 167
4. G. Leoncini, F. Viazzi, and D. Parodi Mild renal dysfunction and cardiovascular risk in hypertensive patients J Am Soc Nephrol 15 Suppl 1 2004 S88 S90
5. Y. Nishizawa, T. Shoji, and K. Maekawa Intima-media thickness of carotid artery predicts cardiovascular mortality in hemodialysis patients Am J Kidney Dis 41 2003 S76 S79
6. R. Fathi, B. Haluska, and N. Isbel The relative importance of vascular structure and function in predicting cardiovascular events J Am Coll Cardiol 43 2004 616 623
7. C. van Guldener, J. Lambert, and M.J. Janssen Endothelium-dependent vasodilatation and distensibility of large arteries in chronic haemodialysis patients Nephrol Dial Transplant 12 Suppl 2 1997 14 18
8. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
9. Commonwealth Department of Health and Ageing Schedule of pharmaceutical benefits 2004 Australian Government Canberra
10. The CARI Guidelines (Caring for Australians with Renal Impairment). Australian Kidney Foundation and Australia New Zealand Society of Nephrology, 2002 Available at: http://www.kidney.org.au/CARI/guidelines.php [Accesses July 13, 2005]
11. R. Fathi, N. Isbel, and L. Short The effect of long-term aggressive lipid lowering on ischemic and atherosclerotic burden in patients with chronic kidney disease Am J Kidney Dis 43 2004 45 52
12. W.D. Dupont, and W.D. Plummer Jr. Power and sample size calculations. A review and computer program Control Clin Trials 11 1990 116 128
13. P. Gaede, P. Vedel, and N. Larsen Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 348 2003 383 393
14. S. Agewall, B. Fagerberg, and G. Berglund Multiple risk intervention trial in high risk hypertensive men: comparison of ultrasound intima-media thickness and clinical outcome during 6 years of follow-up J Intern Med 249 2001 305 314
15. M. Mercuri, M.G. Bond, and C.R. Sirtori Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study Am J Med 101 1996 627 634
16. R. Salonen, K. Nyyssonen, and E. Porkkala Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries Circulation 92 1995 1758 1764
17. T.J. Smilde, S. van Wissen, and H. Wollersheim Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial Lancet 357 2001 577 581
18. H.N. Hodis, W.J. Mack, and L. LaBree Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized controlled clinical trial Ann Intern Med 124 1996 548 556
19. C. Wanner, V. Krane, and W. Marz Randomized controlled trial on the effiacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics Kidney Blood Press Res 27 2004 259 266
20. E.M. Wrone, J.M. Hornberger, and J.L. Zehnder Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease J Am Soc Nephrol 15 2004 420 426
21. C. van Guldener, M.J. Janssen, and J. Lambert No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients Nephrol Dial Transplant 13 1998 106 112
22. M.W. Krause, M. Massing, and A. Kshirsagar Combination therapy improves survival after acute myocardial infarction in the elderly with chronic kidney disease Ren Fail 26 2004 715 725
23. P.A. McCullough, K.R. Sandberg, and S. Borzak Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease Am Heart J 144 2002 226 232
24. C. Baigent, M. Landray, and C. Leaper First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease Am J Kidney Dis 45 2005 473 484
25. K. Kalantar-Zadeh, G. Block, and M.H. Humphreys Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients Kidney Int 63 2003 793 808
26. M.E. Suliman, P. Barany, and K. Kalantar-Zadeh Homocysteine in uraemia-a puzzling and conflicting story Nephrol Dial Transplant 2004
27. E.G. Lowrie, and N.L. Lew Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities Am J Kidney Dis 15 1990 458 482
28. J. Zimmermann, S. Herrlinger, and A. Pruy Inflammation enhances cardiovascular risk and mortality in hemodialysis patients Kidney Int 55 1999 648 658
29. P.M. Ridker, C.P. Cannon, and D. Morrow C-reactive protein levels and outcomes after statin therapy N Engl J Med 352 2005 20 28
30. K. Iseki, M. Yamazato, and M. Tozawa Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients Kidney Int 61 2002 1887 1893
31. Y. Liu, J. Coresh, and J.A. Eustace Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition JAMA 291 2004 451 459
32. R. Kennedy, C. Case, and R. Fathi Does renal failure cause an atherosclerotic milieu in patients with end-stage renal disease? Am J Med 110 2001 198 204
33. D.S. Celermajer, K.E. Sorensen, and V.M. Gooch Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis Lancet 340 1992 1111 1115
34. B.F. Culleton, M.G. Larson, and P.W. Wilson Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency Kidney Int 56 1999 2214 2219
35. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22